The approach to treatment of acute myeloid leukemia is substantially influenced by the age of the patient. Younger patients who are arbitrarily defined as those being <60 years, although comprising the minority of all patients with the disease, will always receive an intensive approach, whereas in older patients, an initial decision as to whether an intensive approach is appropriate or not has to be made. Standard chemotherapy for many years has been ‘3+7’, followed by consolidation with high-dose Ara-C at a daily dose level of 3 g/m². It remains unclear as to what number of total treatment courses is optimal. Alternatives to this standard of care will be considered.

急性髓性白血病的治疗方法很大程度上受患者年龄的影响。被任意定义为 <60 岁的年轻患者，尽管在所有患有该疾病的患者中占少数，但总是会接受强化治疗，而在老年患者中，关于强化治疗是否合适的初步决定被制造。多年来的标准化疗一直是“3+7”，然后以每日 3 g/m ²的剂量水平使用高剂量 Ara-C 进行巩固。目前尚不清楚多少疗程的总疗程是最佳的。将考虑替代该护理标准。